TY - JOUR
T1 - A case of IgA vasculitis developing in a patient with Crohn’s disease treated with adalimumab
AU - Yamamoto, Harujiro
AU - Wakisaka, Yusuke
AU - Aoki, Yasuhiro
AU - Kayashima, Atsuto
AU - Matsunaga, Takahiro
AU - Watanabe, Kazuyo
AU - Fukuhara, Seiichiro
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Japanese Society of Gastroenterology 2026.
PY - 2026/4
Y1 - 2026/4
N2 - This study aimed to investigate a suggestive case of IgA vasculitis that developed following acute tonsillitis in a patient with Crohn’s disease treated with adalimumab. IgA vasculitis and Crohn’s disease can both cause abdominal pain, joint pain, and erythema, making an early diagnosis difficult. When they occur together, it can be challenging to determine which is the primary condition. Due to similar symptoms, a careful assessment and thorough understanding of each disease’s characteristics are essential for an accurate diagnosis and proper management. In this case, the overlapping of immunological events due to anti-tumor necrosis factor-ɑ (TNF-ɑ) agents and infection, in addition to pre-existing immune abnormalities, may be contributing factors to the development of IgA vasculitis. Based on this experience, we suggest that patients with inflammatory bowel disease receiving anti-TNF-ɑ agents should be monitored not only for the relapse of their underlying disease but also for the development of IgA vasculitis following tonsillitis.
AB - This study aimed to investigate a suggestive case of IgA vasculitis that developed following acute tonsillitis in a patient with Crohn’s disease treated with adalimumab. IgA vasculitis and Crohn’s disease can both cause abdominal pain, joint pain, and erythema, making an early diagnosis difficult. When they occur together, it can be challenging to determine which is the primary condition. Due to similar symptoms, a careful assessment and thorough understanding of each disease’s characteristics are essential for an accurate diagnosis and proper management. In this case, the overlapping of immunological events due to anti-tumor necrosis factor-ɑ (TNF-ɑ) agents and infection, in addition to pre-existing immune abnormalities, may be contributing factors to the development of IgA vasculitis. Based on this experience, we suggest that patients with inflammatory bowel disease receiving anti-TNF-ɑ agents should be monitored not only for the relapse of their underlying disease but also for the development of IgA vasculitis following tonsillitis.
KW - Adalimumab
KW - Anti-TNF-ɑ agents
KW - Crohn’s disease
KW - IgA vasculitis
UR - https://www.scopus.com/pages/publications/105030847857
UR - https://www.scopus.com/pages/publications/105030847857#tab=citedBy
U2 - 10.1007/s12328-026-02291-7
DO - 10.1007/s12328-026-02291-7
M3 - Article
C2 - 41729401
AN - SCOPUS:105030847857
SN - 1865-7257
VL - 19
SP - 462
EP - 465
JO - Clinical journal of gastroenterology
JF - Clinical journal of gastroenterology
IS - 2
ER -